- Home
- BRID vs HLVX Comparison
BRID vs HLVX Comparison
Compare BRID & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRID
- HLVX
- Stock Information
- Founded
- BRID 1932
- HLVX 2020
- Country
- BRID United States
- HLVX United States
- Employees
- BRID N/A
- HLVX N/A
- Industry
- BRID Specialty Foods
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- BRID Consumer Staples
- HLVX Health Care
- Exchange
- BRID Nasdaq
- HLVX Nasdaq
- Market Cap
- BRID 79.1M
- HLVX 87.6M
- IPO Year
- BRID N/A
- HLVX 2022
- Fundamental
- Price
- BRID $8.68
- HLVX $1.89
- Analyst Decision
- BRID
- HLVX Hold
- Analyst Count
- BRID 0
- HLVX 5
- Target Price
- BRID N/A
- HLVX $2.33
- AVG Volume (30 Days)
- BRID 9.3K
- HLVX 124.1K
- Earning Date
- BRID 08-23-2024
- HLVX 11-07-2024
- Dividend Yield
- BRID N/A
- HLVX N/A
- EPS Growth
- BRID N/A
- HLVX N/A
- EPS
- BRID N/A
- HLVX N/A
- Revenue
- BRID $231,734,000.00
- HLVX N/A
- Revenue This Year
- BRID N/A
- HLVX N/A
- Revenue Next Year
- BRID N/A
- HLVX N/A
- P/E Ratio
- BRID N/A
- HLVX N/A
- Revenue Growth
- BRID N/A
- HLVX N/A
- 52 Week Low
- BRID $7.77
- HLVX $1.55
- 52 Week High
- BRID $14.69
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- BRID 39.31
- HLVX 50.42
- Support Level
- BRID $8.70
- HLVX $1.80
- Resistance Level
- BRID $9.22
- HLVX $2.02
- Average True Range (ATR)
- BRID 0.33
- HLVX 0.08
- MACD
- BRID -0.01
- HLVX 0.01
- Stochastic Oscillator
- BRID 9.86
- HLVX 41.86
About BRID Bridgford Foods Corporation
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are processing and distribution of frozen products, and processing and distribution of snack food products. It includes products such as biscuits, bread dough items, roll dough items, dry sausage products, and beef jerky. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. It derives a majority of its revenue from snack food products.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.